Brief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Mon 14:22
BRIEF-Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing Oct 19 (Reuters) - Ultragenyx Pharmaceutical Inc. RARE.O:
ENTERS SETTLEMENT AGREEMENT WITH NAVINTA ON DOJOLVI PATENT LITIGATION - SEC FILING
NAVINTA LICENSED TO MARKET GENERIC DOJOLVI FROM JANUARY 1, 2033 - SEC FILING
LICENSE PERIOD MAY EXTEND TO JULY 1, 2033 IF PEDIATRIC EXCLUSIVITY GRANTED - SEC FILING
SIMILAR PATENT LITIGATION AGAINST OTHER DOJOLVI ANDA FILERS RELATED TO DOJOLVI REMAINS PENDING - SEC FILING
Source text: [ID:n0001193125-26-424739]
Further company coverage: RARE.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx